[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin. 2018; DOI:10.3322/caac.21442.
[2] Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2019. Toronto, ON: Canadian Cancer Society. 2019. https://cancer.ca/Canadian-Cancer-Statistics-2019-EN. Accessed 25 May 2020.
[3] Maurer T, Eiber M, Schwaiger M, et al. Current use of PSMA–PET in prostate cancer management. Nat Rev Urol. 2016; DOI:10.1038/nrurol.2016.26.
[4] De Jong IJ, Pruim J, Elsinga PH, et al. Visualization of prostate cancer with 11C-choline positron emission tomography. Eru Urol. 2002;42(1):18-23.
[5] Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. The J Nucl Med. 1998;39(6):990.
[6] Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27(9):1415-9.
[7] Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014; DOI:10.1007/s00259-013-2525-5.
[8] Schwenck J, Rempp H, Reischl G, et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017; DOI:10.1007/s00259-016-3490-6.
[9] Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging and Biol. 2015; DOI:10.1007/s11307-015-0866-0.
[10] Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005; DOI:10.1148/radiol.2352040494.
[11] Igerc I, Kohlfürst S, Gallowitsch HJ, et al. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; DOI:10.1007/s00259-007-0686-9.
[12] Häcker A, Jeschke S, Leeb K, et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. The J Urol. 2006; DOI:10.1016/j.juro.2006.07.037.
[13] Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?. Mol Imaging Biol. 2006; DOI:10.1007/s11307-005-0023-2.
[14] Jadvar H. Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline. J Nucl Med. 2011; DOI:10.2967/jnumed.110.077941.
[15] Afshar-Oromieh A, Sattler LP, Mier W, et al. The clinical impact of additional late PET/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med. 2017; DOI:10.2967/jnumed.116.183483.
[16] Rowe SP, Macura KJ, Mena E, et al. PSMA-based [18F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016; DOI:10.1007/s11307-016-0957-6.
[17] Wondergem M, van der Zant FM, Knol RJ, et al. 18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution. J Nucl Med. 2017; DOI:10.2967/jnumed.117.192658.
[18] Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F] DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011; DOI:10.1158/1078-0432.CCR-11-1357.
[19] Yang DM, Palma D, Louie A, et al. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid 18F‐fluorodeoxyglucose‐positron emission tomography and CT perfusion study. J Med Imaging Radiat Onco. 2019; DOI:10.1111/1754-9485.12807.
[20] Keyes Jr JW. SUV: standard uptake or silly useless value?. J Nucl Med. 1995;36(10):1836-9.
[21] Schaefferkoetter JD, Wang Z, Stephenson MC, et al. Quantitative 18 F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring. EJNMMI Res. 2017; DOI:10.1186/s13550-017-0269-0.
[22] Verwer EE, Oprea-Lager DE, van den Eertwegh AJ, et al. Quantification of 18F-fluorocholine kinetics in patients with prostate cancer. J Nucl Med. 2015; DOI:10.2967/jnumed.114.148007.
[23] Jansen BH, Yaqub M, Voortman J, Cysouw MC, Windhorst AD, Schuit RC, Kramer GM, van den Eertwegh AJ, Schwarte LA, Hendrikse NH, Vis AN. Simplified methods for quantification of 18F-DCFPyL uptake in patients with prostate cancer. J Nucl Med. 2019; DOI:10.2967/jnumed.119.227520.
[24] Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, Souvatzogluou M, Gildehaus FJ, Wester HJ, Dresel S. Value of 11 C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007; DOI:10.1007/s00259-006-0190-7.
[25] Schwarzenböck S, Souvatzoglou M, Krause BJ. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics. 2012; DOI:10.7150/thno.4008.
[26] Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC. Initial evaluation of [18F] DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015; DOI:10.1007/s11307-015-0850-8.
[27] Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, de Jong IJ. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging. 2005; DOI:10.1007/s00259-004-1741-4.
[28] Quak E, Blanchard D, Houdu B, et al. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging. 2018; DOI:10.1007/s00259-017-3911-1.